ArticleEndocrine2017
Epidemiology, management and outcomes of Graves' disease-real life data.
Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Likelihood of Laryngeal Involvement in Autoimmune Thyroid Disorder Patients: A Meta-Analysis.Endocrine, metabolic & immune disorders drug targets · 2025Pooled it
- An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts.The Journal of clinical endocrinology and metabolism · 2020Pooled it
- Autoimmunity and peginterferon therapy for polycythemia vera.HemaSphere · 2026Review
- Disparities in utilization of high-volume thyroid surgeons for Graves disease: a statewide analysis.Journal of the Endocrine Society · 2026Article
- The Broad Effect of Iodine in Graves' Hyperthyroidism and Its Relationship with the Gut Microbiota.Nutrients · 2026Review
- Article
- Volatile hydrocarbon exposures and immune-related illnesses among Deepwater Horizon oil spill workers.Journal of exposure science & environmental epidemiology · 2026Article
- Article
- Clinical Phenotype of Graves Disease in Autoimmune Polyglandular Syndrome or as Isolated Disease: The GRAPHE Study.The Journal of clinical endocrinology and metabolism · 2025Observational
- Article
- Thyroid-Targeted Nano-Bombs Empower HIFU for Graves' Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Predictors of Remission in Graves' Disease Patients Treated With Antithyroid Drugs: A Retrospective Study.Cureus · 2025Article
- Autoimmune Thyroid Disease and Pregnancy: The Interaction Between Genetics, Epigenetics and Environmental Factors.Journal of clinical medicine · 2024Review
- Article
- Mechanisms underlying sex differences in autoimmunity.The Journal of clinical investigation · 2024Review
- Thyroid Eye Disease and Glaucoma: A Cross-Sectional Study Comparing Clinical Characteristics and Disease Severity.Medicina (Kaunas, Lithuania) · 2024Article
- Medullary Thyroid Carcinoma in Patients with Graves' Disease-A Case Series and Literature Review.Journal of clinical medicine · 2024Article
- An Appraisal of the Preventive Effect of Statins on the Development of Graves' Ophthalmopathy: A Hospital-Based Cohort Study.Ophthalmology and therapy · 2024Article
- Article
- Graves disease is associated with increased risk of clinical Alzheimer's disease: evidence from the Medicare system.Clinical diabetes and endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment options in Graves' disease are clearly defined, but management practices and the perceptions of success are varied. The outcomes of treatment in large consecutive cohorts of Graves' disease have not been well characterised. The study describes the epidemiology, management strategies and medium term outcomes following anti-thyroid drug treatment, radio-iodine ablation and surgery in Graves' disease.
methodsAll patients (n = 659) who received treatment for a new diagnosis of Graves' disease in secondary care over a 5 year period were included with a median (interquartile range) follow-up of 42.9 (29-57.5) months.
resultsThe age adjusted incidence of adult onset Graves' disease in Sheffield, UK was 24.8 per 100,000 per year. Excluding 35 patients lost to follow-up, 93.1% (n = 581) were controlled on anti-thyroid drug treatment. Of these, 73.6% went into remission following withdrawal of anti-thyroid drugs; 5.2% were still undergoing initial therapy; 13.3% lost control whilst on anti-thyroid drugs; and 7.9% went on to have either surgery or radio-iodine ablation whilst controlled on anti-thyroid drugs. Of the 428 patients who achieved remission, 36.7% relapsed. Of 144 patients who had radio-iodine ablation treatment, 5.6% relapsed and needed further treatment. Of 119 patients having surgery, 5.2% had long-term hypoparathyroidism and none had documented long-term recurrent laryngeal nerve palsy.
conclusionsIn the follow-up, 39.9% of patients underwent surgery or radio-iodine ablation with little morbidity. Up to two-thirds of patients who achieved remission did not relapse. Data on effectiveness and risks of treatments for Graves' disease presented in this study will help clinicians and patients in decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.